Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | See Remarks | June 11, 2021 | June 14, 2021 |
| FATE THERAPEUTICS INCFATE · Entity 5968 | Chief Development Officer | May 15, 2018 | May 16, 2018 |
| Turnstone Biologics Corp.TSBX · Entity 76646 | Chief Scientific Officer | October 16, 2023 | October 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 11, 2021 · Filed June 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.75 · Expires 2031-06-10 | Direct | 5,000 |
Reported balance
After 2021-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The shares underlying this option shall vest in twelve equal monthly installments commencing on June 11, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest in twelve equal monthly installments commencing on June 11, 2021.
FATE THERAPEUTICS INC
Report date May 15, 2018 · Filed May 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,917 |
Ending reported balance
After 2018-05-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-05-15 · Exercise / conversion · Acquired 2,916 · Balance 46,779 Row 2 · 2018-05-15 · Exercise / conversion · Acquired 18,138 · Balance 64,917 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.89 · Expires 2025-10-15 | Direct | 67,084 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Exercise / conversion · Disposed 2,916 · Balance 67,084 F2: Not applicable. F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on November 12, 2015, such that this option is fully exercisable on October 12, 2019, subject to the recipient's continued service relationship with the Issuer. This option is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2025-08-03 | Direct | 51,862 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Exercise / conversion · Disposed 18,138 · Balance 51,862 F2: Not applicable. F3: The shares subject to the option shall vest and become exercisable at the rate of 1/4th of the shares on July 13, 2016 and 1/48th of the shares each month thereafter such that this option is fully exercisable on July 13, 2019. This option is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on November 12, 2015, such that this option is fully exercisable on October 12, 2019, subject to the recipient's continued service relationship with the Issuer. This option is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
F2: Not applicable.
F3: The shares subject to the option shall vest and become exercisable at the rate of 1/4th of the shares on July 13, 2016 and 1/48th of the shares each month thereafter such that this option is fully exercisable on July 13, 2019. This option is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
Turnstone Biologics Corp.
Report date October 16, 2023 · Filed October 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2033-10-15 | Direct | 45,542 |
Reported balance
After 2023-10-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-10-16 · Grant · Acquired 45,542 · Balance 45,542 F1: One fourth (1/4th) of the shares subject to the option award shall vest on October 12, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4th) of the shares subject to the option award shall vest on October 12, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2023 Filed Oct 17, 2023 18:35 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | GrantEmployee Stock Option (Right to Buy) · Derivative | 45,542 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001209191-23-052993 · doc4.xml · derivative · entry 1 ABBOT STEWART · CIK 0001655597 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,542 Underlying: Common Stock · 45,542 shares Expires 2033-10-15 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on October 12, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 20:28 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantNon-Qualified Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001209191-21-040232 · doc4.xml · derivative · entry 1 ABBOT STEWART · CIK 0001655597 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The shares underlying this option shall vest in twelve equal monthly installments commencing on June 11, 2021. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 02:18 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 106,900 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000899243-21-007032 · doc4.xml · derivative · entry 1 ABBOT STEWART · CIK 0001655597 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,900 Underlying: Common Stock · 106,900 shares Expires 2031-02-11 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:30 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $13.27 | $0.00 |
DisclosureSEC source: 0000899243-21-002188 · doc4.xml · derivative · entry 1 ABBOT STEWART · CIK 0001655597 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-01-12 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 01:50 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantIncentive Stock Option (right to buy) · Derivative | 63,751 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0000899243-20-025646 · doc4.xml · derivative · entry 3 ABBOT STEWART · CIK 0001655597 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,751 Underlying: Common Stock · 63,751 shares Expires 2030-09-17 F5 · derivative.exercise_date: 1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Dr. Abbot remains in continuous service as of the applicable vesting date. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:50 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantEmployee Stock Option (right to buy) · Derivative | 57,151 | Not disclosed Strike: $5.97 | Not disclosed |
DisclosureSEC source: 0000899243-20-025646 · doc4.xml · derivative · entry 2 ABBOT STEWART · CIK 0001655597 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,151 Underlying: Common Stock · 57,151 shares Expires 2029-10-15 F4 · price: Received in exchange for an employee stock option to acquire 460,900 shares of common stock of Old Adicet for $0.740 per share in connection with the Merger. F3 · derivative.exercise_date: 1/48th of the option vests on each of the forty-eight (48) monthly anniversaries of October 15, 2019, provided that Dr. Abbot remains in continuous service as of the applicable vesting date. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:50 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantEmployee Stock Option (right to buy) · Derivative | 84,791 | Not disclosed Strike: $2.26 | Not disclosed |
DisclosureSEC source: 0000899243-20-025646 · doc4.xml · derivative · entry 1 ABBOT STEWART · CIK 0001655597 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,791 Underlying: Common Stock · 84,791 shares Expires 2028-08-14 F2 · price: Received in exchange for an employee stock option to acquire 683,800 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.280 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." F1 · derivative.exercise_date: 25% of the option vested on June 27, 2019, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Abbot remains in continuous service as of the applicable vesting date. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:28 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 18,138 | Not disclosed Strike: $6.90 | Not disclosed |
DisclosureSEC source: 0001209191-18-030617 · doc4.xml · derivative · entry 4 ABBOT STEWART · CIK 0001655597 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,862 Underlying: Common Stock · 18,138 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F3 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable at the rate of 1/4th of the shares on July 13, 2016 and 1/48th of the shares each month thereafter such that this option is fully exercisable on July 13, 2019. This option is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:28 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 2,916 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001209191-18-030617 · doc4.xml · derivative · entry 3 ABBOT STEWART · CIK 0001655597 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,084 Underlying: Common Stock · 2,916 shares Expires 2025-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on November 12, 2015, such that this option is fully exercisable on October 12, 2019, subject to the recipient's continued service relationship with the Issuer. This option is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:28 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 18,138 | $6.90 | $125,152.20 |
DisclosureSEC source: 0001209191-18-030617 · doc4.xml · nonDerivative · entry 2 ABBOT STEWART · CIK 0001655597 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 16, 2018 21:28 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 2,916 | $4.89 | $14,259.24 |
DisclosureSEC source: 0001209191-18-030617 · doc4.xml · nonDerivative · entry 1 ABBOT STEWART · CIK 0001655597 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 186,000 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001209191-18-003918 · doc4.xml · derivative · entry 1 ABBOT STEWART · CIK 0001655597 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,000 Underlying: Common Stock · 186,000 shares Expires 2028-01-15 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-17-002628 · doc4.xml · derivative · entry 1 ABBOT STEWART · CIK 0001655597 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.